Cited 7 times in
The protective effect of thalidomide on left ventricular function in a rat model of diabetic cardiomyopathy
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 장혁재 | - |
dc.date.accessioned | 2015-04-23T16:57:09Z | - |
dc.date.available | 2015-04-23T16:57:09Z | - |
dc.date.issued | 2010 | - |
dc.identifier.issn | 1388-9842 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/101543 | - |
dc.description.abstract | AIMS: To evaluate the protective effect of thalidomide, a potent anti-inflammatory drug, on the development of diabetic cardiomyopathy (DMCMP). METHODS AND RESULTS: We induced type 1 diabetes using streptozocin in 8-week-old Sprague-Dawley rats, divided them into two groups-a thalidomide treatment group (DM-T, n = 15) and a non-treatment group (DM-N, n = 15)-and compared them with a normal control (n = 10). Ten weeks after diabetes induction, heart and lung mass indices were higher in the DM-N group compared with the control group. In the DM-T group, increases in heart and lung mass indices were attenuated compared with the DM-N group. On echocardiographic examination, systolic and diastolic mitral annulus velocities were impaired in the DM-N group, but they remained normal in the DM-T group. On haemodynamic analyses, left ventricular (LV) systolic function, represented by end-systolic elastance (0.35 ± 0.14 vs. 0.18 ± 0.07 mmHg/μl, P < 0.001) and preload-recruitable stroke work (90.5 ± 24.3 vs. 51.8 ± 22.0 mmHg, P < 0.001), was preserved in the DM-T group compared with the DM-N group. Likewise, deterioration of LV diastolic function was attenuated in the DM-T group. Increases in serum levels of TNF-α were attenuated in the DM-T group compared with the DM-N group. On histological analysis, thalidomide treatment lowered total myocardial collagen content and the expression of TNF-α, IL-1β, ICAM-1, and VCAM-1. CONCLUSION: In an animal model of DMCMP, deterioration of LV systolic and diastolic function was partially prevented by thalidomide treatment | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 1051~1060 | - |
dc.relation.isPartOf | EUROPEAN JOURNAL OF HEART FAILURE | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Analysis of Variance | - |
dc.subject.MESH | Animals | - |
dc.subject.MESH | Antibiotics, Antineoplastic/pharmacology | - |
dc.subject.MESH | Collagen/drug effects | - |
dc.subject.MESH | Diabetes Mellitus, Type 1* | - |
dc.subject.MESH | Diabetic Cardiomyopathies/diagnostic imaging | - |
dc.subject.MESH | Diabetic Cardiomyopathies/drug therapy* | - |
dc.subject.MESH | Fibrosis | - |
dc.subject.MESH | Heart Ventricles/diagnostic imaging | - |
dc.subject.MESH | Heart Ventricles/drug effects* | - |
dc.subject.MESH | Hemodynamics | - |
dc.subject.MESH | Hypertrophy, Left Ventricular/drug therapy | - |
dc.subject.MESH | Immunosuppressive Agents/pharmacology* | - |
dc.subject.MESH | Immunosuppressive Agents/therapeutic use | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Matrix Metalloproteinase 9 | - |
dc.subject.MESH | Rats | - |
dc.subject.MESH | Rats, Sprague-Dawley | - |
dc.subject.MESH | Statistics, Nonparametric | - |
dc.subject.MESH | Streptozocin/pharmacology | - |
dc.subject.MESH | Systole | - |
dc.subject.MESH | Thalidomide/pharmacology* | - |
dc.subject.MESH | Thalidomide/therapeutic use | - |
dc.subject.MESH | Ultrasonography | - |
dc.subject.MESH | Ventricular Function, Left/drug effects* | - |
dc.title | The protective effect of thalidomide on left ventricular function in a rat model of diabetic cardiomyopathy | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Kim Dae-Hee | - |
dc.contributor.googleauthor | Kim Yong-Jin | - |
dc.contributor.googleauthor | Chang Sung-A | - |
dc.contributor.googleauthor | Lee Hye-Won | - |
dc.contributor.googleauthor | Kim Ha-Na | - |
dc.contributor.googleauthor | Kim Hyung-Kwan | - |
dc.contributor.googleauthor | Chang Hyuk-Jae | - |
dc.contributor.googleauthor | Sohn Dae-Won | - |
dc.contributor.googleauthor | Park Young-Bae | - |
dc.identifier.doi | 10.1093/eurjhf/hfq103 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A03490 | - |
dc.relation.journalcode | J00823 | - |
dc.identifier.eissn | 1879-0844 | - |
dc.identifier.pmid | 20601373 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1093/eurjhf/hfq103/abstract | - |
dc.subject.keyword | Diabetic cardiomyopathy | - |
dc.subject.keyword | halidomide | - |
dc.subject.keyword | Streptozocin | - |
dc.subject.keyword | Ventricular function | - |
dc.contributor.alternativeName | Chang, Hyuck Jae | - |
dc.contributor.affiliatedAuthor | Chang, Hyuck Jae | - |
dc.citation.volume | 12 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1051 | - |
dc.citation.endPage | 1060 | - |
dc.identifier.bibliographicCitation | EUROPEAN JOURNAL OF HEART FAILURE, Vol.12(10) : 1051-1060, 2010 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.